Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing

dc.contributor.authorLorenzi, Luisa
dc.contributor.authorDöring, Claudia
dc.contributor.authorRausch, Tobias
dc.contributor.authorBenes, Vladimir
dc.contributor.authorLonardi, Silvia
dc.contributor.authorBugatti, Mattia
dc.contributor.authorCampo Güerri, Elias
dc.contributor.authorCabeçadas, José
dc.contributor.authorSimonitsch-Klupp, Ingrid
dc.contributor.authorBorges, Anita
dc.contributor.authorMehta, Jay
dc.contributor.authorAgostinelli, Claudio
dc.contributor.authorPileri, Stefano Aldo
dc.contributor.authorFacchetti, Fabio
dc.contributor.authorHansmann, Martin-Leo
dc.contributor.authorHartmann, Sylvia
dc.date.accessioned2018-03-19T10:39:56Z
dc.date.available2018-03-19T10:39:56Z
dc.date.issued2017-01-27
dc.date.updated2018-03-19T10:39:56Z
dc.description.abstractFollicular dendritic cell (FDC)-sarcoma is a rare neoplasm with morphologic and phenotypic features of FDCs. It shows an extremely heterogeneous morphology, therefore, its diagnosis relys on the phenotype of tumor cells. Aim of the present study was the identification of new specific markers for FDC-sarcoma by whole transcriptome sequencing (WTS). Candidate markers were selected based on gene expression level and biological function. Immunohistochemistry was performed on reactive tonsils, on 22 cases of FDC-sarcomas and 214 control cases including 114 carcinomas, 87 soft tissue tumors, 5 melanomas, 5 thymomas and 3 interdigitating dendritic cell sarcomas. FDC secreted protein (FDCSP) and Serglycin (SRGN) proved to be specific markers of FDC and related tumor. They showed better specificity and sensitivity values than some well known markers used in FDC sarcoma diagnosis (specificity: 98.6%, and 100%, respectively; sensitivity: 72.73% and 68.18%, respectively). In our cohorts CXCL13, CD21, CD35, FDCSP and SRGN were the best markers for FDC-sarcoma diagnosis and could discriminate 21/22 FDC sarcomas from other mesenchymal tumors by linear discriminant analysis. In summary, by WTS we identified two novel FDC markers and by the analysis of a wide cohort of cases and controls we propose an efficient marker panel for the diagnosis of this rare and enigmatic tumor.
dc.format.extent10 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec671346
dc.identifier.issn1949-2553
dc.identifier.pmid28145886
dc.identifier.urihttps://hdl.handle.net/2445/120860
dc.language.isoeng
dc.publisherImpact Journals
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.18632/oncotarget.14864
dc.relation.ispartofOncotarget, 2017, vol. 8, num. 10, p. 16463-16472
dc.relation.urihttps://doi.org/10.18632/oncotarget.14864
dc.rightscc-by (c) Lorenzi, Luisa et al., 2017
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Fonaments Clínics)
dc.subject.classificationCèl·lules dendrítiques
dc.subject.classificationMalalties rares
dc.subject.classificationTumors
dc.subject.otherDendritic cells
dc.subject.otherRare diseases
dc.subject.otherTumors
dc.titleIdentification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
671346.pdf
Mida:
10.6 MB
Format:
Adobe Portable Document Format